When was Orthobond founded?

Orthobond was founded in 2004 and raised its 1st funding round 7 years after it was founded.

Where is Orthobond located?

Orthobond is headquartered in North Brunswick, United States.

How many employees does Orthobond have?

As of Jan 31, 2026, the latest employee count at Orthobond is 21.

Is Orthobond a funded company?

Orthobond is a funded company, having raised a total of $3.22M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 21, 2011.

When was the latest funding round of Orthobond?

Orthobond's latest funding was a $***** Series A round on Sep 15, 2022, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $942M in funding in 2026 to date.

Where does Orthobond rank among its competitors?

Orthobond ranks 125th amongst 1100 active competitors, of which 71 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Caidya, which secured $165M in Jan, 2025.

Who are the top competitors of Orthobond?

Orthobond's top competitors include WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals. Among them, Caidya secured the most recent funding round in January, 2025.

Orthobond - 2026 Company Profile, Team, Funding & Competitors

Orthobond is a series A company based in North Brunswick (United States), founded in 2004 by Jeffery Schwartz. It operates as a Functionalized anti-microbial surface coatings for medical devices. Orthobond has raised $3.22M in funding. The company has 1100 active competitors, including 71 funded and 128 that have exited. Its top competitors include companies like WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals.

Key Metrics

Founded Year

2004

Location

North Brunswick, United States

Stage

Series A

Total Funding

$3.22M in 3 rounds

Latest Funding Round

Series A, Sep 15, 2022, $*****

Investors

HHS

Ranked

125^th among 1100 active competitors

Employee Count

21 as on Jan 31, 2026

Similar Companies

WuXi AppTec & 1144 more

View Orthobond's full profile

Orthobond has raised a total funding of $3.22M over 3 rounds. Its first funding round was on Oct 21, 2011. Orthobond has 1 institutional investor.

Here is the list of recent funding rounds of Orthobond:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 15, 2022	5529189	Series A	2925025	1220534	5483560	3506062
Apr 15, 2022	4893021	Grant (prize money)	5356045	3759216	6322865	HHS
Oct 21, 2011	1824151	Series A	2307169	2801697	6407450	1367658

Access funding benchmarks and valuations. Sign up today!

View details of Orthobond's funding rounds and investors

The founders of Orthobond is Jeffery Schwartz.

Here are the details of Orthobond's key team members:

Jeffery Schwartz: Founder of Orthobond.

View details of Orthobond's Founder profiles and Board Members

Orthobond's employee count trend

Orthobond has 21 employees as of Jan 26. Here is Orthobond's employee count trend over the years:

Uncover Orthobond's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orthobond include WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals. Here is the list of Top 10 competitors of Orthobond, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	75/100
2nd	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	72/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	JPMorgan Chase, Ampersand Capital & 4 others	64/100
4th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	63/100
5th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
7th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	North Sky Capital, Pantheon International ... & 3 others	57/100
8th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	55/100
9th	Caidya 2003, Morrisville (United States), Series C	CRO focused on clinical development for phases II & III clinical trials and regulatory affair services	$373M	Qiming Venture Partners, Fidelity Investments ... & 22 others	54/100
10th	Red Nucleus 2014, Yardley (United States), Acquired	Provider of advisory, scientific and medical communications for pharmaceutical industry	-	Maranon Capital, Renovus Capital Partners	52/100
125th	Orthobond 2004, North Brunswick (United States), Series A	Functionalized anti-microbial surface coatings for medical devices	$3.22M	HHS	33/100